Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lemaitre Vascular (LMAT) Research & Development (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Research & Development for 16 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 2.35% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.1 million through Dec 2025, down 9.65% year-over-year, with the annual reading at $14.1 million for FY2025, 9.65% down from the prior year.
  • Research & Development for Q4 2025 was $3.5 million at Lemaitre Vascular, up from $3.0 million in the prior quarter.
  • The five-year high for Research & Development was $4.5 million in Q2 2023, with the low at $2.7 million in Q2 2021.
  • Average Research & Development over 5 years is $3.6 million, with a median of $3.5 million recorded in 2022.
  • The sharpest move saw Research & Development surged 35.75% in 2021, then decreased 18.76% in 2025.
  • Over 5 years, Research & Development stood at $3.5 million in 2021, then increased by 2.81% to $3.6 million in 2022, then grew by 22.43% to $4.4 million in 2023, then dropped by 16.85% to $3.6 million in 2024, then decreased by 2.35% to $3.5 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $3.5 million, $3.0 million, and $3.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.